Top Picks based on the theme biotechnology and pharmaceutical
The intensity of success or failure is very high in Biotechnology industry. Companies spend hundreds of millions of dollars, on research and development for decades and can face no success. If they get hold of success, its intensity will be life changing for investors and company, at the same time failures burn huge amount of money and human efforts.
Every industry faces success and failures, however the drastic ups and downs that the biotechnology stocks witnesses is not possible in any other industry. If the fruits of a research and development reaches its patients, it will not only save their lives, it will turnaround the fortunes of the company and its shareholders.
Air and water pollution and global warming are indirectly impacting the health of many people and lately there is a vast increase in working people becoming lethargic due to unhealthy habits. All these ill effects are causing temporary and permanent health illnesses that require treatment and frequent and/or lifelong medication. Biotechnology companies with broad range of drugs in their kitty and strong pipeline of drugs is what you need to look in the biotechnology industry to add excellent value to your portfolio through Biotech stocks.
Top Picks based on the theme Biotechnology/Pharmaceutical
Experts at Stock Chase has selected Biotechnology companies that has high prospects to generate sound earning results and strong investment return.
Bruce Murray, CEO & Chief Investment Officer at The Murray Wealth Group recommends Medtronic Inc (MDT-N),
Medtronic Inc, received approval from U.S. Food and Drug Administration (FDA) for its automated insulin delivery controlling sensor the Guardian™ Sensor 3 in February 2018. The company also received approval for its Resolute Onyx 2.0 mm Drug-Eluting Stent technology intended to treat patients with coronary artery disease (CAD) who have small vessels. The launch of these two products substantially increases the positive sentiment on the stock.
Mark Grammer, Managing Director & Portfolio Manager at Gluskin Sheff & Associates recommends Novartis AG (NVS-N),
Cameron Hurst, Chief Investment Officer at Equium Capital Management recommends Edwards Lifesciences Corp (EW-N),
David Baskin, President at Baskin Wealth Management recommends Becton Dickinson (BDX-N),
Bruce Murray, CEO & Chief Investment Officer at The Murray Wealth Group recommends Astrazeneca P L C (AZN-N),
Due to changing lifestyles, increased number of factors having ill effects on human health and their growing intensity are increasing the usage and use cases of medicines for various diseases. Selecting the right Biotech candidates for your portfolio will drastically increases the chances of increased outperformance in terms of return compared to market performance.
Top 11 Biotechnology Links Referred to in this Post
- Medtronic Inc
- Novartis AG
- Edwards Lifesciences Corp
- Becton Dickinson
- Astrazeneca P L C
- The biotech sector: A primer
- Key Figures on established biotech centers worldwide 2012-2016
- Medtronic Inc, received approval for its automated insulin delivery sensor
- Medtronic Launches First 2.0 mm Drug-Eluting Stent
- Why you feel sleepy at work
- Global Climate Change